CoTOL is a standard Chinese language drugs (TCM) formulation in clinics for treating gout and hyperuricemia, particularly in overweight sufferers with recurrent assaults. Nevertheless, fewer research have investigated how CoTOL impacts the intestinal flora in lowering uric acid. Within the current, we analyze the micro organism focused by elements of CoTOL and consider the consequences of CoTOL on uric acid and intestinal flora in a mice mannequin of overweight hyperuricemia inoculated with xanthine dehydrogenase- (XOD-) producing micro organism, Streptococcus faecalis detected by the adequate antibody.
Firstly, elements of herbs in CoTOL and gene goal by these elements have been retrieved from TCMID 2.0, and these genes have been screened by DAVID Bioinformatics Assets 6.8, deciphered to retrieve the micro organism. Then, 3-4-week-old male C57bl/6j mice have been randomly divided into 6 teams and fed with excessive fats weight loss program for Eight weeks as much as weight problems normal.
The mice have been inoculated intragastrically with 5 × 109 CFU Streptococcus faecalis Three instances on the 5th, 6th, and seventh week and intragastrically administrated with uricase inhibitor, potassium-oxonate (PO, 250 mg/kg), to induce hyperuricemia on the 8th week, as soon as a day for 7 consecutive days, respectively (IB mannequin). IB mannequin plus CoTOL (0.Four ml/20g) and allopurinol (40 mg/kg) have been administrated by gavage on the 5th week, as soon as a day for Four weeks. The feces and blood in every group have been sampled on the 4th and eightth week.
With no micro organism inoculation, CoTOL, allopurinol, and clean group have been handled with CoTOL and allopurinol or water, respectively. 44 species of micro organism (i.e., Enterococcus faecalis, Streptococcus, and so on.) genes have been focused by 6 elements of 6 herbs in CoTOL. Inoculation with Streptococcus faecalis considerably precipitated the elevation of uric acid and the change of intestinal flora construction, whereas therapy with CoTOL significantly elevated the abundance of Akkermansia and people of Bacteroides and Alloprevotella decreased.
Moreover, CoTOL exhibited a singular impact on lowering weight unobserved in allopurinol intervention. The current examine, for the primary time, demonstrated that CoTOL has useful results on hyperuricemia and chubby, which can be attributed to regulating materials metabolism and enhancing the construction or perform of intestinal flora. Thus, CoTOL could also be a promising remedy for hyperuricemia and chubby in persistent gout administration and might be built-in with standard therapies.
8-Hydroxy-2′-Deoxyguanosine and 8-Nitroguanine Manufacturing and Detection in Blood Serum of Breast Most cancers Sufferers in Response to Postoperative Complementary Exterior Ionizing Irradiation of Regular Tissues
It’s broadly recognized that ionizing irradiation is strongly linked to the manufacturing of reactive oxygen (ROS) and nitrative species (RNS) by means of which DNA harm merchandise like 8-hydroxy-2-deoxyguanosine (8-OHdG) and 8-nitroguanine (8-NG) are generated, respectively. Within the current examine, we aimed to research the formation of 8-OHdG and 8-NG upon irradiation and to additional discover whether or not alterations of their focus ranges are associated to the administered radiation doses and publicity time. Our analysis work was carried out in blood serum samples collected from 33 breast most cancers sufferers who acquired adjuvant radiotherapy.
The detection of 8-OHdG and 8-NG was assessed by enzyme-linked immunosorbent assay. Our outcomes counsel that each, 8-OHdG and 8-NG, have been fashioned through the radiation routine. Vital correlations with radiation dose have been additionally demonstrated by the dose-response curves of 8-OHdG and 8-NG, fitted by logarithmic distribution and polynomial regression, respectively.
Extra exactly, 8-OHdG and 8-NG concentrations (ng/mL) have been significantly elevated when sufferers acquired ionizing radiation as much as 30 Gy whereas irradiation over 30 Gy didn’t induce any additional will increase. The present examine helps a) the manufacturing of 8-OHdG and 8-NG throughout radiotherapy and b) important correlations between both 8-OHdG or 8-NG ranges and radiation doses, indicating a radiation-dose-dependent relationship.
α-Amylase assay with starch-iodine-sodium fluorescein-based fluorometric technique in human serum samples
A brand new fluorometric technique was developed for the dedication of α-amylase exercise in human serum samples. Firstly, a saturated starch-iodine complicated (SI) was ready. The SI complicated was mixed with sodium fluorescein to kind a starch-iodine-sodium fluorescein complicated (SIF). Because the SIF complicated decomposes with the α-amylase enzymatic hydrolysis of starch, the depth of its fluorescence emission will increase. The α-amylase exercise is decided utilizing the elevated fluorescence emission depth following hydrolysis of the SIF complicated by α-amylase.
The optimum pH, optimum buffer focus, optimum temperature, and interference impact have been recognized for the developed fluorometric measurement technique. Below the optimum circumstances, a linear calibration curve was obtained between 0.18 and 9.00 U/L for α-amylase. The α-amylase exercise within the human serum pattern was additionally decided by our ready measurement system and in contrast with the outcome from a medical middle. Each strategies are in good settlement with one another.
As a result of this newly developed fluorometric technique for α-amylase exercise in serum samples is cheap, straightforward to make use of, and carried out to detect a really low quantity of human serum α-amylase with sensitivity, it may be proposed this technique for alpha-amylase exercise assay in all different organic samples.
Impaired host response and the presence of Acinetobacter baumannii within the serum microbiome of type-II diabetic sufferers
Kind II diabetes (T2D) impacts over 10% of the US inhabitants and is a rising illness worldwide that manifests with quite a few comorbidities and defects in irritation. This dysbiotic host response permits for an infection of the host by quite a few microorganisms. In the midst of T2D illness, people can develop persistent infections together with foot ulcers and periodontitis, which result in additional issues and opportunistic infections in a number of physique websites.
 Antibody) Serum Amyloid A (SAA) Antibody |
|
abx022450-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
|
Serum Amyloid A (SAA) Antibody |
|
abx022451-1mg |
Abbexa |
1 mg |
EUR 1220.4 |
|
|
Serum Amyloid A (SAA) Antibody |
|
abx022452-05mg |
Abbexa |
0.5 mg |
EUR 1680 |
|
|
Serum Amyloid A (SAA) Antibody |
|
20-abx101239 |
Abbexa |
-
EUR 477.60
-
EUR 159.60
-
EUR 1328.40
-
EUR 644.40
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Serum Amyloid A (SAA) Antibody |
|
20-abx101240 |
Abbexa |
-
EUR 493.20
-
EUR 159.60
-
EUR 1362.00
-
EUR 661.20
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Serum Amyloid A (SAA) Antibody |
|
20-abx101241 |
Abbexa |
-
EUR 510.00
-
EUR 159.60
-
EUR 1412.40
-
EUR 693.60
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Serum Amyloid A (SAA) Antibody |
|
48336-100ul |
SAB |
100ul |
EUR 399.6 |
Serum Amyloid A (SAA) Antibody |
|
48336-50ul |
SAB |
50ul |
EUR 286.8 |
 Serum Amyloid A Antibody / SAA1 + SAA2 |
|
V7345-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This antibody reacts with natural and recombinant human Serum Amyloid A (SAA) and does not cross-react with other human cytokines or growth factors. Human SAA proteins are a group of apo-lipoproteins found predominantly in the high-density lipoprotein (HDL) fraction of plasma. SAA is a major acute-phase protein and precursor to amyloid A protein, which is the major constituent of the fibril deposits of reactive amyloidosis. SAA is secreted in large amounts by the liver during microbial infections or inflammatory diseases. |
Serum Amyloid A Antibody / SAA1 + SAA2 |
|
V7345-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: This antibody reacts with natural and recombinant human Serum Amyloid A (SAA) and does not cross-react with other human cytokines or growth factors. Human SAA proteins are a group of apo-lipoproteins found predominantly in the high-density lipoprotein (HDL) fraction of plasma. SAA is a major acute-phase protein and precursor to amyloid A protein, which is the major constituent of the fibril deposits of reactive amyloidosis. SAA is secreted in large amounts by the liver during microbial infections or inflammatory diseases. |
Serum Amyloid A Antibody / SAA1 + SAA2 |
|
V7345IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
|
Description: This antibody reacts with natural and recombinant human Serum Amyloid A (SAA) and does not cross-react with other human cytokines or growth factors. Human SAA proteins are a group of apo-lipoproteins found predominantly in the high-density lipoprotein (HDL) fraction of plasma. SAA is a major acute-phase protein and precursor to amyloid A protein, which is the major constituent of the fibril deposits of reactive amyloidosis. SAA is secreted in large amounts by the liver during microbial infections or inflammatory diseases. |
Serum Amyloid A Antibody / SAA1 + SAA2 |
|
V7345SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This antibody reacts with natural and recombinant human Serum Amyloid A (SAA) and does not cross-react with other human cytokines or growth factors. Human SAA proteins are a group of apo-lipoproteins found predominantly in the high-density lipoprotein (HDL) fraction of plasma. SAA is a major acute-phase protein and precursor to amyloid A protein, which is the major constituent of the fibril deposits of reactive amyloidosis. SAA is secreted in large amounts by the liver during microbial infections or inflammatory diseases. |
Serum Amyloid A Antibody / SAA1 + SAA2 |
|
RQ5313 |
NSJ Bioreagents |
100ul |
EUR 356.15 |
|
Description: Serum amyloid A (SAA) proteins are a family of apolipoproteins associated with high-density lipoprotein (HDL) in plasma. Different isoforms of SAA are expressed constitutively (constitutive SAAs) at different levels or in response to inflammatory stimuli (acute phase SAAs). These proteins are produced predominantly by the liver. The conservation of these proteins throughout invertebrates and vertebrates suggests that SAAs play a highly essential role in all animals. [Wiki] |
Serum Amyloid A Antibody / SAA1 + SAA2 |
|
V7516-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This antibody reacts with natural and recombinant human Serum Amyloid A (SAA) and does not cross-react with other human cytokines or growth factors. Human SAA proteins are a group of apo-lipoproteins found predominantly in the high-density lipoprotein (HDL) fraction of plasma. SAA is a major acute-phase protein and precursor to amyloid A protein, which is the major constituent of the fibril deposits of reactive amyloidosis. SAA is secreted in large amounts by the liver during microbial infections or inflammatory diseases. |
Serum Amyloid A Antibody / SAA1 + SAA2 |
|
V7516-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: This antibody reacts with natural and recombinant human Serum Amyloid A (SAA) and does not cross-react with other human cytokines or growth factors. Human SAA proteins are a group of apo-lipoproteins found predominantly in the high-density lipoprotein (HDL) fraction of plasma. SAA is a major acute-phase protein and precursor to amyloid A protein, which is the major constituent of the fibril deposits of reactive amyloidosis. SAA is secreted in large amounts by the liver during microbial infections or inflammatory diseases. |
Serum Amyloid A Antibody / SAA1 + SAA2 |
|
V7516IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
|
Description: This antibody reacts with natural and recombinant human Serum Amyloid A (SAA) and does not cross-react with other human cytokines or growth factors. Human SAA proteins are a group of apo-lipoproteins found predominantly in the high-density lipoprotein (HDL) fraction of plasma. SAA is a major acute-phase protein and precursor to amyloid A protein, which is the major constituent of the fibril deposits of reactive amyloidosis. SAA is secreted in large amounts by the liver during microbial infections or inflammatory diseases. |
Serum Amyloid A Antibody / SAA1 + SAA2 |
|
V7516SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This antibody reacts with natural and recombinant human Serum Amyloid A (SAA) and does not cross-react with other human cytokines or growth factors. Human SAA proteins are a group of apo-lipoproteins found predominantly in the high-density lipoprotein (HDL) fraction of plasma. SAA is a major acute-phase protein and precursor to amyloid A protein, which is the major constituent of the fibril deposits of reactive amyloidosis. SAA is secreted in large amounts by the liver during microbial infections or inflammatory diseases. |
 Antibody) Amyloid A, Serum (SAA) Antibody |
|
abx023988-1mg |
Abbexa |
1 mg |
EUR 1262.4 |
|
|
Amyloid A, Serum (SAA) Antibody |
|
abx023989-1mg |
Abbexa |
1 mg |
EUR 1262.4 |
|
|
Amyloid A, Serum (SAA) Antibody |
|
abx023990-1mg |
Abbexa |
1 mg |
EUR 1262.4 |
|
|
Amyloid A, Serum (SAA) Antibody |
|
abx023991-1mg |
Abbexa |
1 mg |
EUR 1262.4 |
|
|
Amyloid A, Serum (SAA) Antibody |
|
abx024166-1mg |
Abbexa |
1 mg |
EUR 794.4 |
|
|
 Antibody (PE)) Serum Amyloid A (SAA) Antibody (PE) |
|
20-abx274642 |
Abbexa |
-
EUR 543.60
-
EUR 292.80
-
EUR 1579.20
-
EUR 760.80
-
EUR 410.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
 Antibody (APC)) Serum Amyloid A (SAA) Antibody (APC) |
|
20-abx178373 |
Abbexa |
|
|
|
|
 Antibody) Serum Amyloid A (SAA/2868R) Antibody |
|
BNC942868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF594 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC942868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF594 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC802868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF680 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC802868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF680 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC702868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF770 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC702868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF770 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC882868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF488A conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC882868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF488A conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC812868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF680R conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC812868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF680R conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC402868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF640R conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC402868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF640R conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC052868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF405M conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC052868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF405M conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC042868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF405S conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC042868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF405S conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNCAP2868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNCAP2868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNCA2868-250 |
Biotium |
250uL |
EUR 472.8 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), APC conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNCP2868-250 |
Biotium |
250uL |
EUR 472.8 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), PerCP conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNCR2868-250 |
Biotium |
250uL |
EUR 472.8 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), RPE conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNCH2868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNCH2868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNCB2868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), Biotin conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNCB2868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), Biotin conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNUB2868-100 |
Biotium |
100uL |
EUR 316.8 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), Concentration: 0.2mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNUB2868-50 |
Biotium |
50uL |
EUR 486 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), 1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNUB2868-500 |
Biotium |
500uL |
EUR 615.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), Concentration: 0.2mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC472868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF647 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC472868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF647 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC552868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF555 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC552868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF555 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC612868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF660R conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC612868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF660R conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC432868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF543 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC432868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF543 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC682868-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF568 conjugate, Concentration: 0.1mg/mL |
Serum Amyloid A (SAA/2868R) Antibody |
|
BNC682868-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against Serum Amyloid A (SAA/2868R), CF568 conjugate, Concentration: 0.1mg/mL |
 Antibody Pair) Serum Amyloid A (SAA) Antibody Pair |
|
20-abx370045 |
Abbexa |
|
- 10 × 96 tests
- 5 × 96 tests
|
|
|
Serum Amyloid A (SAA) Antibody Pair |
|
20-abx370635 |
Abbexa |
|
- 10 × 96 tests
- 5 × 96 tests
|
|
|
Serum Amyloid A (SAA) Antibody Pair |
|
20-abx370785 |
Abbexa |
|
- 10 × 96 tests
- 5 × 96 tests
|
|
|
 Antibody (FITC)) Serum Amyloid A (SAA) Antibody (FITC) |
|
20-abx273736 |
Abbexa |
-
EUR 543.60
-
EUR 292.80
-
EUR 1545.60
-
EUR 744.00
-
EUR 410.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Serum Amyloid A (SAA) Antibody (FITC) |
|
20-abx273958 |
Abbexa |
-
EUR 543.60
-
EUR 292.80
-
EUR 1579.20
-
EUR 760.80
-
EUR 410.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Serum Amyloid A (SAA) Antibody (FITC) |
|
20-abx274059 |
Abbexa |
-
EUR 560.40
-
EUR 292.80
-
EUR 1663.20
-
EUR 777.60
-
EUR 427.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
 Antibody) Human Serum Amyloid A (SAA) Antibody |
|
13011-05011 |
AssayPro |
150 ug |
EUR 260.4 |
 Antibody (Biotin)) Serum Amyloid A (SAA) Antibody (Biotin) |
|
20-abx272067 |
Abbexa |
-
EUR 510.00
-
EUR 276.00
-
EUR 1429.20
-
EUR 693.60
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Serum Amyloid A (SAA) Antibody (Biotin) |
|
20-abx272757 |
Abbexa |
-
EUR 510.00
-
EUR 276.00
-
EUR 1462.80
-
EUR 710.40
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Serum Amyloid A (SAA) Antibody (Biotin) |
|
20-abx273039 |
Abbexa |
-
EUR 543.60
-
EUR 292.80
-
EUR 1545.60
-
EUR 744.00
-
EUR 410.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
Serum Amyloid A (SAA) Antibody (Biotin) |
|
20-abx274604 |
Abbexa |
-
EUR 410.40
-
EUR 243.60
-
EUR 1028.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
|
 Antibody) Serum Amyloid A Protein (saa) Antibody |
|
abx018140-100ug |
Abbexa |
100 ug |
EUR 460.8 |
|
|
 Antibody) Serum Amyloid A Protein (SAA) Antibody |
|
abx415337-01mg |
Abbexa |
0.1 mg |
EUR 526.8 |
|
|
Serum Amyloid A Protein (SAA) Antibody |
|
abx415338-01mg |
Abbexa |
0.1 mg |
EUR 543.6 |
|
|
 Antibody) Serum Amyloid A Protein (SAA1) Antibody |
|
20-abx210169 |
Abbexa |
|
|
|
|
Serum Amyloid A Protein (SAA1) Antibody |
|
20-abx110208 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
Serum Amyloid A Protein (SAA1) Antibody |
|
20-abx109401 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
 Serum Amyloid P Antibody |
|
RQ4226 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
|
Description: Amyloid P component, serum (SAP), also known as PTX2 or APCS, is the identical serum form of amyloid P component (AP), a 25kDa pentameric protein first identified as the pentagonal constituent of in vivo pathological deposits called amyloid. It belongs to the pentraxins family, characterised by calcium dependent ligand binding and distinctive flattened β-jellyroll structure similar to that of the legume lectins. This gene is mapped to 1q23.2. The binding of the encoded protein to proteins in the pathological amyloid cross-beta fold suggests its possible role as a chaperone. This protein is also thought to control the degradation of chromatin. It has been demonstrated that this protein binds to apoptotic cells at an early stage, which raises the possibility that it is involved in dealing with apoptotic cells in vivo. |
Serum Amyloid P Antibody |
|
R31453 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
|
Description: Serum Amyloid P (SAP), also known as PTX2 or APCS, is the identical serum form of amyloid P component (AP), a 25kDa pentameric protein first identified as the pentagonal constituent of in vivo pathological deposits called amyloid. The binding of Serum Amyloid P to proteins in the pathological amyloid cross-beta fold suggests its possible role as a chaperone. This protein is also thought to control the degradation of chromatin. |
Serum Amyloid P Antibody |
|
V7605-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Serum amyloid P (SAP) is a glycoprotein that can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. May also function as a calcium-dependent lectin. [UniProt] |
Serum Amyloid P Antibody |
|
V7605-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: Serum amyloid P (SAP) is a glycoprotein that can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. May also function as a calcium-dependent lectin. [UniProt] |
Serum Amyloid P Antibody |
|
V7605SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Serum amyloid P (SAP) is a glycoprotein that can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. May also function as a calcium-dependent lectin. [UniProt] |
Serum Amyloid P Antibody |
|
V7848-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Serum amyloid P (SAP) is a glycoprotein belonging to the pentraxin family of proteins, which has a characteristic pentameric organization and calciumdependent ligand binding. Secreted by liver epithelial cells, SAP is found in serum and urine. Although the function of SAP has not been clearly established, it has been shown to interact with DNA and histones and is thought to play a role in scavenging nuclear material released from damaged circulating cells. Also designated PTX2, SAP is a precursor of the protein amyloid P component (AP), which is universally associated with the amyloid deposits in all forms of amyloidoses, including Alzheimer s disease. SAP is a decamer of ten identical, noncovalently linked subunits, each of which may be post-translationally modified by glycosylation. |
Serum Amyloid P Antibody |
|
V7848-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: Serum amyloid P (SAP) is a glycoprotein belonging to the pentraxin family of proteins, which has a characteristic pentameric organization and calciumdependent ligand binding. Secreted by liver epithelial cells, SAP is found in serum and urine. Although the function of SAP has not been clearly established, it has been shown to interact with DNA and histones and is thought to play a role in scavenging nuclear material released from damaged circulating cells. Also designated PTX2, SAP is a precursor of the protein amyloid P component (AP), which is universally associated with the amyloid deposits in all forms of amyloidoses, including Alzheimer s disease. SAP is a decamer of ten identical, noncovalently linked subunits, each of which may be post-translationally modified by glycosylation. |
Serum Amyloid P Antibody |
|
V7848SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Serum amyloid P (SAP) is a glycoprotein belonging to the pentraxin family of proteins, which has a characteristic pentameric organization and calciumdependent ligand binding. Secreted by liver epithelial cells, SAP is found in serum and urine. Although the function of SAP has not been clearly established, it has been shown to interact with DNA and histones and is thought to play a role in scavenging nuclear material released from damaged circulating cells. Also designated PTX2, SAP is a precursor of the protein amyloid P component (AP), which is universally associated with the amyloid deposits in all forms of amyloidoses, including Alzheimer s disease. SAP is a decamer of ten identical, noncovalently linked subunits, each of which may be post-translationally modified by glycosylation. |
 Conjugated Antibody) Serum Amyloid A (SAA) Conjugated Antibody |
|
C48336 |
SAB |
100ul |
EUR 476.4 |
 Human Serum amyloid A monoclonal antibody |
|
10R-11479 |
Fitzgerald |
1 mg |
EUR 427.2 |
|
Description: Mouse anti- Human Serum amyloid A protein monoclonal antibody |
 Antibody) Human Serum Amyloid A-4 (SAA4) Antibody |
|
13031-05011 |
AssayPro |
150 ug |
EUR 260.4 |
 Antibody) Serum Amyloid A-1 Protein (SAA1) Antibody |
|
abx237572-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
 Antibody) Serum Amyloid A-2 Protein (SAA2) Antibody |
|
abx237573-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
 Antibody) Serum Amyloid A-4 Protein (SAA4) Antibody |
|
abx237574-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Serum Amyloid A-4 Protein (SAA4) Antibody |
|
abx029249-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Serum Amyloid A-4 Protein (SAA4) Antibody |
|
abx029249-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
Serum Amyloid A-1 Protein (SAA1) Antibody |
|
abx413456-1ml |
Abbexa |
1 ml |
EUR 410.4 |
|
|
Serum Amyloid A-1 Protein (SAA1) Antibody |
|
abx414889-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
|
Serum Amyloid A-1 Protein (SAA1) Antibody |
|
20-abx001392 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
 Antibody (HRP)) Serum Amyloid A Protein (SAA1) Antibody (HRP) |
|
20-abx108750 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
Serum Amyloid A Protein (SAA1) Antibody (HRP) |
|
20-abx109024 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
 Antibody (FITC)) Serum Amyloid A Protein (SAA1) Antibody (FITC) |
|
20-abx107330 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
On this examine, we investigated the serum of wholesome topics and sufferers with T2D with (T2DP) or with out periodontitis for each microbiome signatures along with cytokine profiles. Surprisingly, we detected the presence of Acinetobacter baumanii within the serum of 23% people with T2D/T2DP examined. In T2DP, IL-1β, TNF-α, MCP-1, IL-6, IL-8, and IFN-γ have been considerably elevated in ABC-positive topics. As an rising pathogen, A. baumanii an infection represents a threat for impaired irritation and the event of comorbidities in topics with T2D.
